Zenas BioPharma, Inc.: 5%+ holders

As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Zenas BioPharma, Inc. The largest reported stake is Fmr LLC's, at 14.3%. 18 filings are on record since August 6, 2025 (Schedule 13G/A, February 5, 2026).

Enavate Sciences GP, LLC also filed stake reports on 2 other companies ↓

Sell to companies like Zenas BioPharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-05 · Reporting person: Xencor, Inc. · Sole voting: 1,000,000 · Shared voting: 0 · Sole dispositive: 1,000,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 3,226,537 · Shared voting: 0 · Sole dispositive: 3,287,021 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
• Filing 2026-09-08 · Reporting person: InnoCare Pharma Inc. · Sole voting: 0 · Shared voting: 7,000,000 · Sole dispositive: 0 · Shared dispositive: 7,000,000 · SCHEDULE 13G/A, 2026-09-08
• Filing 2026-09-08 · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 6,308,474 · Sole dispositive: 0 · Shared dispositive: 6,566,134 · SCHEDULE 13G, 2026-09-08
• Event date 2026-08-19 · Holder: Enavate Sciences GP, LLC · Percent: 4.9% · Shares: 3,245,404 · SCHEDULE 13D/A

Zenas BioPharma, Inc. has 18 Schedule 13D or 13G filings on record since 2025-08-06. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Zenas BioPharma, Inc. and the warning signs.

See Zenas BioPharma, Inc.'s free Snapshot Watch Zenas BioPharma, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Zenas BioPharma, Inc. and the records around it.

Zenas BioPharma, Inc. elsewhere on the record

• Leadership changes Aug 2026
• Who owns it

Companies that share a holder

• Enavate Sciences GP, LLC also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Mar 2026)
• Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: Lexeo Therapeutics, Inc. (Nov 2025), CG Oncology, Inc. (Sep 2025)
• SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Veradermics, Inc. (Aug 2026), Odyssey Therapeutics, Inc. (May 2026)

Want the whole picture on Zenas BioPharma, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Zenas BioPharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Zenas BioPharma, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   22 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Zenas BioPharma, Inc. by CUSIP 98937L105 and gives its principal executive office as 852 Winter Street, Suite 250, Waltham, MA 02451 (SCHEDULE 13G/A, 2026-11-05).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.InnoCare Pharma Inc., SCHEDULE 13G/A, 2026-09-08

1.5% This percentage is calculated based upon 65,176,723 shares of the Issuer's Common Stock outstanding as of July 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026.Xencor, Inc., SCHEDULE 13G/A, 2026-11-05

Source of funds (Item 3)

Not applicable.SR One Capital Management, LLC, SCHEDULE 13D/A, 2026-08-17

Purpose of Transaction (Item 4)

Moulder Leon O Jr

The information set forth in Item 3 of this Statement is incorporated herein by reference. Mr. Moulder serves as the Chairman of the Issuer's Board of Directors and as its Chief Executive Officer. In such capacity, Mr. Moulder has influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons reserve the right to formulate in the future plans or proposals which may relate to or result in the transactions described in subparagraphs (a) through (j) of this Item 4. In addition to the foregoing, the Reporting Persons may engage in discussions from time to time with other members of the Issuer's management and/or Board of Directors and/or with other stockholders of the Issuer and/or other third parties. Such discussions may include, without limitation, discussions with respect to the governance, board composition, management, operations, business, assets, capitalization, financial condition, strategic plans and future of the Issuer, as well as other matters related to the Issuer. These discussions may also include a review of options for enhancing stockholder value through, among other things, various strategic alternatives …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-05; the filing has the rest

Longitude Capital Partners IV, LLC

The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2025-10-14

SR One Capital Management, LLC

Not applicable.Item 4 of the SCHEDULE 13D/A filed 2026-08-17

Timeline

Swipe the table sideways to see every column.

Questions about who owns Zenas BioPharma, Inc.

Who owns Zenas BioPharma, Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of Zenas BioPharma, Inc.: Fmr LLC (14.3%, Schedule 13G/A, filed 2026-02-05), InnoCare Pharma Inc. (10.4%, Schedule 13G/A, filed 2026-09-08), Wellington Management Group LLP (10.1%, Schedule 13G, filed 2026-09-08), SR One Capital Management, LLC (7.7%, Schedule 13D/A, filed 2026-08-17) and Moulder Leon O Jr (5.09%, Schedule 13D, filed 2026-05-05); 1 more is listed above.

Who are the largest shareholders of Zenas BioPharma, Inc.?

By the share each holder's latest filing reports, the largest holders of Zenas BioPharma, Inc. on this page are Fmr LLC (14.3%), InnoCare Pharma Inc. (10.4%) and Wellington Management Group LLP (10.1%).

When did Fmr LLC buy into Zenas BioPharma, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-08-06, reporting 7.9%; its latest, Schedule 13G/A filed 2026-02-05, reports 14.3%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Zenas BioPharma, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Zenas BioPharma, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Zenas BioPharma, Inc. is mentioned again
• Find former Zenas BioPharma, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes